Explore

Immunomic Therapeutics Begins Phase 1 Trial for Cancer Vaccine ITI-5000 Targeting Triple-Negative Breast Cancer

Immunomic Therapeutics Begins Phase 1 Trial for Cancer Vaccine ITI-5000 Targeting Triple-Negative Breast Cancer

Immunomic Therapeutics, Inc., a biotechnology company based in Rockville, Maryland, has announced the commencement of a Phase 1 clinical trial for its cancer vaccine candidate, ITI-5000. This investigational vaccine is designed to treat triple-negative breast cancer (TNBC) and is being tested in a multicenter, open-label, first-in-human study. The trial aims to evaluate the safety, tolerability, and preliminary immunologic activity of ITI-5000 in patients with Stage II–III TNBC, both as a monotherapy and in combination with standard adjuvant therapy. The first participant has been dosed, and no significant adverse events have been reported. ITI-5000 utilizes Immunomic's proprietary UNITE® platform and next-generation self-amplifying RNA (saRNA) technology to generate a targeted T cell immune response against tumor-associated antigens.

Massive Bio and FOMAT Collaborate to Enhance Cancer Patient Access to Clinical Trials

Massive Bio and FOMAT Collaborate to Enhance Cancer Patient Access to Clinical Trials

Massive Bio, a global precision oncology company, has partnered with FOMAT, the largest Embedded Research Organization in the United States, to improve cancer patient prescreening for clinical trials using AI technology. This collaboration, initiated in June 2026, aims to streamline the process of identifying eligible patients for oncology clinical trials across FOMAT's community-based research network. The partnership is currently in a pilot phase, testing the efficiency of integrating AI into the prescreening process. This initiative is designed to reduce the time between diagnosis and trial enrollment, particularly benefiting underserved communities that have historically been underrepresented in clinical research.

Jeremy Clarkson's Prostate Cancer Treatment Highlights Potential of Focal Therapy

Jeremy Clarkson's Prostate Cancer Treatment Highlights Potential of Focal Therapy

A 10-year study led by Imperial College London has found that focal therapy, a targeted treatment for prostate cancer, may be as effective as traditional methods like surgery or radiotherapy, with fewer side effects. Jeremy Clarkson, who underwent this treatment, has brought attention to its benefits. The study followed nearly 3,500 men and found that focal therapy significantly reduces the risk of complications such as urinary incontinence and erectile dysfunction, while maintaining effective cancer control.

Johns Hopkins Surgeon Highlights AI Breakthrough in Early Pancreatic Cancer Detection

Johns Hopkins Surgeon Highlights AI Breakthrough in Early Pancreatic Cancer Detection

Johns Hopkins Surgeon Highlights AI Breakthrough in Early Pancreatic Cancer Detection

Weill Cornell Medicine Develops AI Tool to Enhance Monitoring of Myelodysplastic Neoplasms

Weill Cornell Medicine Develops AI Tool to Enhance Monitoring of Myelodysplastic Neoplasms

Researchers at Weill Cornell Medicine have developed a new AI-based method to improve the assessment of patients with myelodysplastic neoplasms (MDS), a form of blood cancer. This method, detailed in the journal Leukemia, involves comparing the physical locations and morphometric characteristics of hematopoietic cells in a patient's bone marrow with those in healthy samples. The resulting MDS-Microarchitectural Perturbation Score (MDS-MAPS) provides a numerical value indicating disease severity. This tool aims to offer more precise diagnoses and track disease progression over time, potentially improving patient care. The AI method uses routinely collected samples and imaging technologies that can be implemented in most hospital pathology departments.

UCLA Study Suggests Creatine Supplements May Enhance Cancer-Fighting Immune Cells

UCLA Study Suggests Creatine Supplements May Enhance Cancer-Fighting Immune Cells

Researchers at the University of California, Los Angeles (UCLA) have discovered that creatine supplements, commonly used for muscle building, may also play a role in cancer treatment. The study, published in iScience, indicates that creatine can enhance the function of dendritic cells, which are crucial for activating the body's killer T cells to fight cancer. The research team found that dendritic cells from tumors produced more of the creatine transporter protein (CrT) than those from healthy tissue, suggesting a potential mechanism for creatine's role in boosting immune response. By experimenting with dendritic cells lacking CrT, researchers observed reduced activity and effectiveness in preparing T cells to combat tumors. This study builds on previous findings that creatine boosts killer T cell activity, suggesting a broader role in energizing the immune infrastructure.

UCLA Study Finds Creatine Supplements May Enhance Cancer Treatment by Boosting Immune Response

UCLA Study Finds Creatine Supplements May Enhance Cancer Treatment by Boosting Immune Response

Researchers at the University of California, Los Angeles (UCLA) have discovered that creatine supplements, commonly used for muscle building, may also play a significant role in cancer treatment. The study, published in iScience, reveals that creatine can enhance the function of dendritic cells, which are crucial for activating the body's killer T cells to fight cancer. The research team found that dendritic cells from tumors produce more of the creatine transporter protein, which facilitates creatine's entry into cells, compared to those from healthy tissue. By experimenting with dendritic cells lacking this transporter, the researchers observed reduced activity and effectiveness in preparing T cells for an anti-cancer response. This suggests that creatine not only supports T cells but also energizes the entire immune infrastructure involved in combating cancer.

UCLA Study Suggests Creatine Supplements May Enhance Cancer Treatment

UCLA Study Suggests Creatine Supplements May Enhance Cancer Treatment

Researchers at the University of California, Los Angeles (UCLA) have discovered that creatine supplements could play a role in cancer treatment by boosting the activity of dendritic cells, which are crucial in the immune response against tumors. The study, published in iScience, found that creatine injections in mice slowed tumor growth and increased the activity of dendritic cells. These cells, which help detect tumor cells and activate killer T cells, showed enhanced function when supplemented with creatine. The research also explored the effects of creatine on human dendritic cells in a laboratory setting, suggesting potential benefits for human cancer therapy.

Model's Battle with Aggressive Breast Cancer Leads to Life-Saving Move to Arizona

Model's Battle with Aggressive Breast Cancer Leads to Life-Saving Move to Arizona

Alison McCullough, a model from Alaska, faced significant challenges in receiving timely treatment for an aggressive form of breast cancer. Initially, she struggled to get a diagnosis due to age-related screening guidelines and limited healthcare options in Alaska. After being diagnosed with triple-negative breast cancer, a form that is difficult to treat due to the absence of certain receptors, McCullough faced further delays in starting chemotherapy. Concerned about the growing cancer and the wait times, she and her husband decided to seek treatment elsewhere. They contacted City of Hope, a cancer research and treatment organization, and quickly relocated to Phoenix, Arizona, where she began receiving treatment. McCullough underwent chemotherapy and a double mastectomy, and by May, she was declared cancer-free.

Model Relocates for Breast Cancer Treatment Amid Healthcare Access Challenges

Model Relocates for Breast Cancer Treatment Amid Healthcare Access Challenges

Alison McCullough, a model from Alaska, faced significant challenges in accessing timely breast cancer treatment due to her age and location. Diagnosed with triple-negative breast cancer, a particularly aggressive form, McCullough struggled to receive a mammogram because she was under 40, the recommended age for regular screenings. After a delayed diagnosis and limited treatment options in Alaska, she relocated to Phoenix, Arizona, to receive care at City of Hope, a cancer research and treatment organization. This move allowed her to begin treatment promptly, which included chemotherapy and a double mastectomy. McCullough's story highlights the barriers to healthcare access and the critical need for timely intervention in cancer treatment.

Study Links Unhealthy Gut to Breast Cancer Metastasis, Suggests New Treatment Avenues

Study Links Unhealthy Gut to Breast Cancer Metastasis, Suggests New Treatment Avenues

A recent study conducted by the University of Virginia Comprehensive Cancer Center has revealed that an unhealthy gut microbiome may contribute to the spread of hormone receptor-positive breast cancer. The research, led by Melanie Rutkowski, Ph.D., indicates that an imbalance in gut microorganisms can lead to a buildup of bile acids, which disrupts metabolism and immune function, creating conditions conducive to cancer metastasis. The study highlights that hormone receptor-positive breast cancer is the most common form of metastatic breast cancer, affecting approximately 225,000 American women annually. The findings suggest that modifying bile acid composition or using bile acid sequestrants, which are already FDA-approved for metabolic diseases, could potentially reduce cancer spread.

New Imaging Method Enhances Cancer Tracking from Whole Body to Cellular Level

New Imaging Method Enhances Cancer Tracking from Whole Body to Cellular Level

Researchers have developed a new imaging method that allows for the tracking of cancer progression from the whole body down to individual cells. This approach combines multiple imaging techniques, such as PET scans, bioluminescence, and fluorescence, to detect tumors across the body and examine them in detail. The method, demonstrated in liver and lung cancer models, provides a clearer understanding of tumor behavior at both macro and micro levels. This advancement could lead to more precise cancer treatments by allowing researchers to study tumors individually rather than treating them as biologically identical. The study, led by Professor David Lewis from the Cancer Research UK Scotland Institute and University of Glasgow, is published in Nature Biotechnology.